COMP <GO>
NXTC vs RNAZ // DIVIDEND YIELD & FCF PAYOUT SAFETY
NextCure Inc. (NASDAQ) VS. TransCode Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: NXTC 2
— RNAZ 0
■ METRIC PARITY
LAST: $6.53 (+2.92%) • MKT CAP: $29.9M
dividend-safety
0.00%
LAST: $1.73 (-0.57%) • MKT CAP: $29.3M
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NXTC VS. RNAZ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NXTC | RNAZ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.3 | 40.8 | +13.48 | NXTC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $29.9M | $29.3M | $577.1K | NXTC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NXTC REV | RNAZ REV | NXTC GROSS % | RNAZ GROSS % | NXTC FCF | RNAZ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$49.6M | -$19.5M |
| FY 2024 | $0 | $0 | — | — | -$41.3M | -$13.4M |
| FY 2023 | $0 | $0 | — | — | -$53.0M | -$18.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NXTC // BETA —
RNAZ // BETA —